CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

ABSTRACT:

Purpose

Although CD49d is an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL), definitive validation evidence is lacking. A worldwide multicenter analysis was performed using published and unpublished CLL series to evaluate the impact of CD49d as an overall (OS) and treatment-free survival (TFS) predictor.

Patients and methods

A training/validation strategy was chosen to find the optimal CD49d cutoff. The hazard ratio (HR) for death and treatment imposed by CD49d was estimated by pooled analysis of 2,972 CLLs; Cox analysis stratified by center and stage was used to adjust for confounding variables. The importance of CD49d over other flow cytometry-based prognosticators (eg, CD38, ZAP-70) was ranked by recursive partitioning.

Results

Patients with ≥

SUBMITTER: Bulian P 

PROVIDER: S-EPMC4876311 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature